Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy individuals as controls. Peripheral blood samples were collected from newly diagnosed pancreatic cancer patients and healthy individuals. Using techniques such as plasma TCR/BCR-seq, CyTOF, and plasma proteomics, multi-modal individual immune characteristics were obtained and analyzed along with clinical information. An artificial intelligence predictive model was built based on these multi-modal individual immune characteristics to establish an early screening technique for pancreatic cancer. The sensitivity and specificity of this artificial intelligence model for early pancreatic cancer diagnosis were evaluated using an external multicenter sample test set.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Sign the informed consent form;
* Initial diagnosis as patients with pancreatic cancer, patients with benign pancreatic lesions, or healthy controls.
Exclusion Criteria:
* History of other malignancies;
* Presence of organ dysfunction;
* Concurrent immunodeficiency syndrome, active tuberculosis, HIV infection, etc.;
* Allogeneic transplantation requiring immunosuppressive therapy;
* Poor follow-up compliance.
Primary outcome measure(s)
Peripheral blood mononuclear cell — During the 1-7 day period before surgery Using RNA seq technology to analyze differentially expressed genes in peripheral immune cells
Peripheral blood mononuclear cell — During the 1-7 day period before surgery TCR/BCR-seq:Using multiple amplification to obtain the CDR3（complementarities determining region3） region of TCR and BCR and analyzing the VDJ rearrangement pattern
Peripheral blood mononuclear cell — During the 1-7 day period before surgery Analyzing RNA expression in individual cells using scRNA-seq
Peripheral blood mononuclear cell — During the 1-7 day period before surgery scTCR/BCR-seq:Using multiple amplification to obtain the CDR3（complementarities determining region3） region of TCR and BCR and analyzing the VDJ rearrangement pattern in individual cells
Peripheral blood mononuclear cell — During the 1-7 day period before surgery Identification of open chromatin regions in individual cells using scATAC-seq technology
Peripheral blood mononuclear cell — During the 1-7 day period before surgery Detecting the abundance and type of some markers for peripheral blood mononuclear cell using CYTOF technology
CT — Within 1 month before surgery Imaging data from the patient's initial visit
MRI — Within 1 month before surgery Imaging data from the patient's initial visit
Trial sites (2)
Facility
City
Region
Status
First Affiliated Hospital, Medical College of Zhejiang University
Hangzhou
Zhejiang
the First Affiliated Hospital, School of Medicine, Zhejiang University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.